BMO Capital Markets launches coverage on Alnylam, BioMarin and Ionis with upbeat ratings

SentiSense · Published Aug 19, 2026, 8:06 AM ET · Updated Aug 19, 2026, 9:53 AM ET

BMO Capital Markets initiated research coverage on three biotech firms on August 19, 2026. The firm assigned an "outperform" rating and a $318 price o...